IMA Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

IMA Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.41K	Buy	77 +25	+48%	+$1.37K	﹤0.01%	945
2026 Q1	$2.94K	Sell	52 -2	-4%	-$117	﹤0.01%	540
2025 Q4	$3.21K	Buy	+54	New	+$2.94K	﹤0.01%	535
2022 Q1	–	Sell	-1,500	Closed	-$133K	–	300
2021 Q4	$133K	Sell	1,500 -32,048	-96%	-$2.64M	0.03%	143
2021 Q3	$2.59M	Buy	33,548 +1,092	+3%	+$86.2K	0.61%	57
2021 Q2	$2.71M	Sell	32,456 -426	-1%	-$33.8K	0.63%	57
2021 Q1	$2.48M	Buy	32,882 +7,350	+29%	+$600K	0.61%	65
2020 Q4	$2.24M	Sell	25,532 -8,553	-25%	-$678K	0.63%	58
2020 Q3	$2.59M	Buy	34,085 +5,151	+18%	+$521K	0.87%	36
2020 Q2	$3.57M	Sell	28,934 -10,298	-26%	-$1.02M	1.29%	22
2020 Q1	$3.31M	Sell	39,232 -2,008	-5%	-$173K	1.46%	17
2019 Q4	$3.49M	Buy	41,240 +521	+1%	+$39.4K	1.29%	22
2019 Q3	$2.74M	Buy	40,719 +3,353	+9%	+$258K	1.04%	35
2019 Q2	$3.2M	Sell	37,366 -2,293	-6%	-$196K	1.2%	29
2019 Q1	$3.52M	Buy	39,659 +704	+2%	+$65.2K	1.37%	21
2018 Q4	$3.32M	Buy	38,955 +941	+2%	+$89.5K	1.55%	15
2018 Q3	$3.69M	Buy	38,014 +2,876	+8%	+$287K	1.44%	18
2018 Q2	$3.31M	Buy	35,138 +417	+1%	+$36.5K	1.38%	19
2018 Q1	$2.81M	Buy	+34,721	New	+$2.98M	1.25%	24

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

IMA Advisory Services's BMRN Position: Q2 2026 in Review

IMA Advisory Services increased its BioMarin Pharmaceuticals (BMRN) stake by 48% in Q2 2026, buying an estimated $1.37K and bringing the position to 77 shares worth $4.41K. The position accounts for ﹤0.01% of the portfolio, ranked #945.

IMA Advisory Services first reported a position in BMRN in Q1 2018 and has held it in 19 quarters since. The position peaked at $3.69M in Q3 2018. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

IMA Advisory Services held 77 shares of BioMarin Pharmaceuticals worth $4.41K as of Q2 2026.
IMA Advisory Services bought 25 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.37K.
BioMarin Pharmaceuticals made up ﹤0.01% of IMA Advisory Services's portfolio in Q2 2026, its #945 holding.
IMA Advisory Services first reported a position in BioMarin Pharmaceuticals in Q1 2018 and has held it in 19 quarters since.
IMA Advisory Services's BioMarin Pharmaceuticals position peaked at $3.69M in Q3 2018.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on IMA Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.